RO-104 / RevOpsis Therap - LARVOL DELTA

RevOpsis and Kemwell Biopharma Enter into Strategic Manufacturing Partnership to Expedite Development of Novel Multispecific Biologics (PRNewswire) - "RevOpsis Therapeutics...and Kemwell Biopharma...announced today a broad strategic manufacturing partnership. This collaboration aims to accelerate the development of RevOpsis' lead candidate, RO-104, a first-in-class tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD). Under this partnership, Kemwell will manufacture RO-104, a novel tri-specific biologic designed to target the three dominant angiogenic pathways (VEGF-A, VEGF-C, Ang-2) for treating nAMD, a leading cause of blindness worldwide....By integrating RevOpsis' next generation plug-and-play multispecific biologics platform with Kemwell's deep biologics development and manufacturing knowledge, the collaboration aims to accelerate therapeutic discovery to IND submission timelines."

Licensing / partnership • Wet Age-related Macular Degeneration